为了恢复纳斯达克的合规性, Cue Biopharma公司执行了1-30股反向分拆. Cue Biopharma executes 1-for-30 reverse stock split to regain Nasdaq compliance.

为了提高股价并恢复纳斯达克的合规性, Cue Biopharma宣布1比30逆向分拆. Cue Biopharma announced a 1-for-30 reverse stock split to raise its share price and regain Nasdaq compliance. 虽然此举并没有阻止股票在新闻上下跌20%,但该公司的股份数量从9770万减至330万. The split, effective April 24, reduces the number of shares from 97.7 million to 3.3 million, though the move did not prevent the stock from dropping 20% on the news.